Entity usage

Jump to navigation Jump to search

This page lists pages that use the given entity (e.g. Q42). The list is sorted by descending page ID, so that newer pages are listed first.

List of pages that use a given entity

Showing below up to 32 results in range #1 to #32.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. Section 1: Introduction (from DOI: 10.1038/s41392-020-0110-5): Title
  2. Competing interests (from DOI: 10.1038/s41392-020-0110-5): Title
  3. Section 5: Conclusions and perspectives (from DOI: 10.1038/s41392-020-0110-5): Title
  4. Section 4.4: CSC-directed immunotherapy (from DOI: 10.1038/s41392-020-0110-5): Title
  5. Section 4.3: Targeting the CSC microenvironment (from DOI: 10.1038/s41392-020-0110-5): Title
  6. Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5): Title
  7. Section 4.1: Agents targeting CSC-associated surface biomarkers in clinical trials (from DOI: 10.1038/s41392-020-0110-5): Title
  8. Section 4: Therapeutic targeting of CSCs (from DOI: 10.1038/s41392-020-0110-5): Title, Statement: P146, Statement: P94, Sitelink, Statement: P78, Statement: P125
  9. Section 3.3.7: Exosomes in the TME and CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  10. Section 3.3.6: Extracellular matrix and CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  11. Section 3.3.5: Cancer-associated MSCs and CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  12. Section 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  13. Section 3.3.3: Tumor-associated macrophages and CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  14. Section 3.3.2: The hypoxia microenvironment and CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  15. Section 3.3.1: Vascular niche microenvironments and CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  16. Section 3.3: The microenvironment of CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  17. Section 3.2.9: Interactions between signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  18. Section 3.2.8: PPAR signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  19. Section 3.2.6: TGF/SMAD signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  20. Section 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5): Title
  21. Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  22. Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  23. Section 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  24. Section 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  25. Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  26. Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  27. Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  28. Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  29. Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  30. Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  31. Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5): Title
  32. Targeting cancer stem cell pathways for cancer therapy (DOI: 10.1038/s41392-020-0110-5): Title

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)